A Phase 1 interventional study of A-319 in Systemic Lupus Erythematosus, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 2 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-17.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2024, is one of 7 in phase 1, and was the 3rd registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–65
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ages 18–70
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 1
First in 2024; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 25 is below the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 12 across the 11 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
6 of the studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | 2026-11 |
| NCT06400537Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus | 2026-12 |
| NCT07031713Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySafety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE | 2026-12-31 |
| NCT07749430Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus | 2027-01-30 |
| NCT07339332Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to explore the safety and efficacy of recombinant CD19xCD3 double antibody (A-319) in active/refractory systemic lupus erythematosus (SLE).
The pathogenic B cells of patients with SLE can produce a large amount of autoantibodies, which will form immune complexes and thereby inducing continuously expanding tissue damage and systemic inflammation. A-319 is a kind of recombinant CD19xCD3 double antibody, it can activate internal T cells to target and kill pathogenic B cells. Clinical trials of A-319 are currently underway in hematological maliganancies concerning B cell abnormality. Preclinical studies have shown the efficacy of A-319 in SLE. The aim of this study is to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary efficacy of A-319 in active/refractory SLE. Patients with active/refractory SLE will be invited to participate in the study, to receive A-319 intravenous infusion or subcutaneous injection and follow-up visits of up to 1 years after enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A-319 will be preset with 3 escalation dose levels by intravenous infusion: dose A, dose B, dose C, total course of treatment: 4 weeks. Anticipated enrollment: 9-18 participants.
Biological: A-319
A-319 will be administered via subcutaneous injection at five preset escalating dose levels: Dose A, Dose B, Dose C, Dose D, and Dose E. The total treatment duration is 4 weeks. Each dose group is planned to enroll 3+N (N=0-12) participants, with a total anticipated enrollment of 16-32 study participants.
Biological: A-319
A-319 will be dosed according to the assigned group.
Safety and tolerability
Safety and tolerability will be assessed by incidence and severity of adverse events (AEs) and serious AEs (SAEs)
Time frame: Within 1 year since A-319 infusion
Pharmacokinetics of A-319
Concentration of A-319 in peripheral blood will be evaluated
Time frame: Within 1 month since A-319 infusion
Pharmacodynamics of A-319
Pharmacodynamics will be assessed by levels of cytokines (IL-6, IL-8, IL-10, IFN-γ, TNF-α) in peripheral blood
Time frame: Within 1 month since A-319 infusion
Pharmacodynamics of A-319
Pharmacodynamics will be assessed by levels of lymphocyte subsets in peripheral blood
Time frame: Within 1 month since A-319 infusion
Numbers of Participants with positive antidrug antibodies in peripheral blood
To evaluate immunogenicity of A-319
Time frame: Day 28 and month 3 since A-319 infusion
Changes in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) from baseline
Range \[0, 105\],higher score represents worse disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in the Physician Global Assessment (PGA) score from baseline
Range \[0, 3\],higher score represents worse disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in the BILAG-2004 score from baseline
Range \[0, 72\],higher score represents worse disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in immunological indexes from baseline
Serum IgA, IgG, IgE and IgM will be evaluated
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in level of anti-nuclear antibody (ANA) in peripheral blood from baseline
To evaluate SLE disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in level of anti-double stranded DNA (dsDNA) antibody in peripheral blood from baseline
To evaluate SLE disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in levels of complement C3 in peripheral blood from baseline
To evaluate SLE disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
Changes in levels of complement C4 in peripheral blood from baseline
To evaluate SLE disease activity
Time frame: Within 1 year since A-319 infusion (day 15, day 28, month 2, month 3, month 4, month 5, month 6, month 9, month 12)
The therapeutic effect of A-319 on impaired organs in active/refractory SLE patients
Pathological samples of impaired organs will be analyzed
Time frame: Within 1 year since A-319 infusion
The clearance effect of A319 on CD19+B cells in active/refractory SLE patients
To evaluate SLE disease activity
Time frame: Within 28 days since A-319 infusion
The effect of A-319 on gene expression in peripheral blood lymphocytes of active/refractory SLE
To investigate the mechanism of action of A-319 in SLE
Time frame: Day 28 and month 3 since A-319 infusion
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 29 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CD3-activating CD19 Bi-specific Antibody A-319
Lupus Erythematosus, Systemic →
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →